Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. | Zendy

Ulrich Keilholz | Zendy; S.H. Goey | Zendy; Cornelis J.A. Punt | Zendy; T. M. Proebstle | Zendy; R Salzmann | Zendy; Carmen Scheibenbogen | Zendy; Dirk Schadendorf | Zendy; D. Liénard | Zendy; Alexander Enk | Zendy; Reinhard Dummer | Zendy; B. Hantich | Zendy; Anne-Marie Geueke | Zendy; Alexander M.M. Eggermont | Zendy

Open Access

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.

Author(s) -

Ulrich Keilholz,

S.H. Goey,

Cornelis J.A. Punt,

T. M. Proebstle,

R Salzmann,

Carmen Scheibenbogen,

Dirk Schadendorf,

D. Liénard,

Alexander Enk,

Reinhard Dummer,

B. Hantich,

Anne-Marie Geueke,

Alexander M.M. Eggermont

Publication year - 1997

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.1997.15.7.2579

Subject(s) - medicine , regimen , alpha interferon , interferon alfa , melanoma , gastroenterology , cytokine , cancer , chemotherapy , randomization , immunotherapy , oncology , randomized controlled trial , surgery , interferon , immunology , cancer research

The combination of interferon alfa-2a (IFN alpha) and high-dose interleukin-2 (IL-2) is active in metastatic melanoma. The addition of cisplatin (CDDP) has resulted in response rates greater than 50%. This study was performed to determine whether the addition of CDDP to a cytokine treatment regimen with IFN alpha and high-dose IL-2 influences survival of patients with metastatic melanoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research